© 2024 HSP News Service, L.L.C.
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses phase III findings from the KEYNOTE-716 study. The trial showed that compared with placebo, adjuvant pembrolizumab significantly improved distant metastasis–free survival in patients with resected stage IIB and IIC melanoma. The findings also suggest a continued reduction in the risk of recurrence and a favorable benefit-risk profile (Abstract LBA9500).
Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine resulted in a 41% reduction in the risk of death. These outcomes, says Dr. Ansell, confirm A+AVD as a preferred option for previously untreated disease (Abstract 7503).
In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), Keung et al reported at the 2022 ASCO Annual Meeting (Abstract LBA11501)....
Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...
Initial results from the ARTISTRY-1 study to be presented by Vaishampayan et al at the 2022 ASCO Annual Meeting showed that an experimental drug called nemvaleukin alfa, when used alone or in combination with pembrolizumab, may be effective in treating several types of late-stage cancers in some...
The addition of nimotuzumab, an EGFR-targeting monoclonal antibody, to gemcitabine increased overall survival in patients with KRAS wild-type advanced pancreatic cancer, particularly those who did not need surgery for obstruction of a pancreatic bile duct, according to data from the phase III...
In a Chinese phase III trial (CAPSTONE-1) reported in The Lancet Oncology, Jie Wang, MD, PhD, and colleagues found that the addition of adebrelimab, a novel anti–PD-L1 antibody, to carboplatin and etoposide significantly improved overall survival as a first-line treatment for patients with...
"The reality is that closure is a myth. My personal and professional experience with those who have lost friends and family, including children, has taught me that going on with life is not the same as gaining closure. The wound of loss is a part of each person’s life forever,” wrote...
On May 27, 2022, the U.S. Food and Drug Administration (FDA) approved the following for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma: Nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-based chemotherapy Nivolumab in...
On May 28, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy....
In analyses from a Spanish phase II trial (NADIM) reported in the Journal of Clinical Oncology, Provencio et al found a high rate of 3-year overall survival in patients with operable stage IIIA non–small cell lung cancer (NSCLC) who received neoadjuvant nivolumab plus chemotherapy. Survival was...
In a phase II trial (CITYSCAPE) reported in The Lancet Oncology, Byoung Chul Cho, MD, and colleagues found that the addition of tiragolumab, an inhibitor of the immune checkpoint molecule TIGIT, to atezolizumab improved objective response rate and progression-free survival in first-line treatment...
A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...
“Progress in lung cancer happens by slow steps punctuated by quantum leaps. In the age of perioperative therapies, we are moving one step closer to curing more patients. Surgery is still the intervention most likely to cure patients with earlier-stage disease, but 50% of cases can recur,” said...
The combination of neoadjuvant nivolumab plus chemotherapy achieved statistically significant and clinically meaningful improvement in event-free survival vs chemotherapy alone (P = .005) in patients with resectable non–small cell lung cancer (NSCLC, stage IB–IIIA), according to the results of the ...
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
As reported in The New England Journal of Medicine by Yuichiro Doki, MD, of Osaka University Graduate School of Medicine, Japan, and colleagues, the phase III CheckMate 648 trial has shown improved overall survival with nivolumab combined with chemotherapy or ipilimumab vs chemotherapy alone in...
On March 21, 2022, pembrolizumab was approved for patients with advanced endometrial carcinoma that is microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), as determined by a U.S. Food and Drug Administration (FDA)-approved test, who have disease progression following prior...
Invited discussant of the NeoCOAST trial, Edward B. Garon, MD, Professor of Medicine and Director of the Thoracic Oncology Program at David Geffen School of Medicine at the University of California Los Angeles, praised the study: “NeoCOAST is an impressive study that showed numerical benefit when...
Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC), according to the results of the phase II NeoCOAST trial presented at the American Association for Cancer Research (AACR)...
Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...
A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...
Treatment with the anti–PD-1 therapy nivolumab after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results...
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...
In a study reported as a letter to the editor in The New England Journal of Medicine, Alexander M. Menzies, MD, and colleagues found that patients with metastatic melanoma who had progressive disease while receiving relatlimab/nivolumab had poor responses to anti–CTLA-4–based treatment. As noted...
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events caused by immunotherapy by targeting the cytokine interleukin-6 (IL-6). The study, published by Hailemichael et al in Cancer Cell, establishes a proof of concept ...
In a single-institution study reported in a research letter in JAMA Oncology, Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer. Study Details The study...
In a single-institution case series reported in a research letter in JAMA Oncology, Terrero et al found that the combination of ipilimumab and nivolumab was active in patients with chemotherapy-refractory metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD)...
In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti–PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell...
The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...
In a phase II trial (DESTINY-Lung01) reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, of the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed...
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...
In a phase II trial (Hoosier Cancer Research Network GU16-260) reported in the Journal of Clinical Oncology, Michael B. Atkins, MD, and colleagues found that nivolumab monotherapy was active in previously untreated patients with advanced clear cell renal carcinoma, particularly among those with...
Ongoing evaluation of novel, targeted, and immunotherapies has led to exciting advances across the array of hematologic malignancies over the past year. The availability of new treatment options, along with emerging data on novel combinations and sequencing approaches, is rapidly changing...
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
As reported in The Lancet Oncology by Thierry Facon, MD, of the Centre Hospitalier Universitaire de Lille, and colleagues, a prespecified interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to...
As reported in The Lancet Oncology by Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, Nantes, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has showed significantly prolonged progression-free survival with maintenance daratumumab vs observation...
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral...
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...
The moderator of the session, Laurie H. Sehn, MD, MPH, Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, called the results of the TRANSFORM trial “quite remarkable” and said chimeric antigen receptor (CAR) T-cell therapy has the...
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel could prove to be the new standard-of-care treatment for patients with relapsed or refractory large B-cell lymphoma in the second-line setting, according to data presented at the 2021 American Society of Hematology (ASH)...
In an interim analysis of the phase II COAST trial reported in the Journal of Clinical Oncology, Roy S. Herbst, MD, PhD, FACP, FASCO, and colleagues found that consolidation durvalumab in combination with the anti-CD73 antibody oleclumab or anti-NKG2A antibody monalizumab both improved objective...
In a study reported in The Lancet Oncology, Robert Motzer, MD, and colleagues found that patients with previously untreated advanced renal cell carcinoma receiving lenvatinib/pembrolizumab had similar or favorable health-related quality of life scores and prolonged time to definitive deterioration...
On May 4, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. According to the approval, patients had to have received a prior anti-HER2–based regimen either in the...
In the Danish single-institution phase II CheckPAC study reported in the Journal of Clinical Oncology, Chen et al found that the combination of nivolumab and ipilimumab plus stereotactic body radiotherapy (SBRT) improved the clinical benefit rate vs nivolumab plus SBRT in patients with refractory...
Chimeric antigen receptor (CAR) T-cell therapy has made an impact on the treatment of certain blood cancers, but in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study ...
Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...
In a meta-analysis reported in JAMA Network Open, Farooq et al found that immune checkpoint inhibitor therapy for cancer was associated with a lower risk of neurologic adverse events compared with treatment with other agents overall in randomized trials comparing immune checkpoint inhibitors with...